Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 1999 Apr 24;318(7191):1104-7.
doi: 10.1136/bmj.318.7191.1104.

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials

G A Knoll  1 , R C Bell
Affiliations
Meta-Analysis

Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials

G A Knoll et al. BMJ. .

Abstract

Objective: To compare tacrolimus with cyclosporin for immunosuppression in renal transplantation.

Design: Meta-analysis of randomised trials of two treatments after kidney transplantation.

Identification: Four studies involving 1037 patients. Trials were included if they were randomised, the intervention group received tacrolimus, the control group received cyclosporin, the patients were followed for a minimum of 12 months, and patient survival, graft survival, incidence of acute rejection, need for antilymphocyte treatment, or the prevalence of diabetes mellitus after transplant was reported.

Main outcome measures: Pooled estimates of patient mortality, allograft loss, and episodes of acute rejection 1 year after transplantation.

Results: The odds ratio for loss of allograft with tacrolimus compared with cyclosporin was 0.95 (95% confidence interval 0.65 to 1.40). The odds ratio for mortality with tacrolimus was 1.07 (0.47 to 2.48). Treatment with tacrolimus was associated with a reduction in episodes of acute rejection (0.52; 0.36 to 0.75), a reduction in the use of antilymphocyte antibodies to treat rejection (0.37; 0.25 to 0. 56), and an increased prevalence of diabetes mellitus after transplantation (5.03; 2.04 to 12.36) compared with treatment with cyclosporin.

Conclusions: After renal transplantation, immunosuppression with tacrolimus results in a significant reduction in acute rejection compared with cyclosporin. Follow up studies of high methodological quality are needed to determine whether tacrolimus improves long term renal graft survival.

PubMed Disclaimer

Comment in

References

    1. US Renal Data System. USRDS 1997 annual data report. Bethesda, Maryland: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April; 1997.
    1. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation. 1995;60:1384–1388. - PubMed
    1. Starzl TE, Fung J, Venkataramman R, Todo S, Demetris AJ, Jain A. FK506 for liver, kidney and pancreas transplantation. Lancet. 1989;ii:1000–1004. - PMC - PubMed
    1. Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, et al. FK506 in clinical kidney transplantation. Transplant Proc. 1991;23:3065–3067. - PMC - PubMed
    1. Ochiai T, Ishibashi M, Fukao K, Takahashi K, Endo T, Yokoyama I, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc. 1995;27:50–53. - PubMed

Publication types